Japan Pharma Database
Pricing: Japan Database: $15,000/- subscription p/a
Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets due to:
1. Operations of various MNCs who generate significant amount of revenue but do not disclose their sales – Market Research Agencies has their limitations; no projections
2. Disclosure of Clinical trial data – is limited/not detailed and is shared after a long gap.
3. Lack of equivalent sites such as clinicaltrials.gov, FDA’s Orange book, etc. – company reports, various categories of CT data available at scattered sources. Mostly in Japanese.
4. Very Difficult to get patent expiry info. from JP cos - Multiple patent extension, NO reliable Source in public domain
5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas companies.
6. Language
Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets due to:
1. Operations of various MNCs who generate significant amount of revenue but do not disclose their sales – Market Research Agencies has their limitations; no projections
2. Disclosure of Clinical trial data – is limited/not detailed and is shared after a long gap.
3. Lack of equivalent sites such as clinicaltrials.gov, FDA’s Orange book, etc. – company reports, various categories of CT data available at scattered sources. Mostly in Japanese.
4. Very Difficult to get patent expiry info. from JP cos - Multiple patent extension, NO reliable Source in public domain
5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas companies.
6. Language
